28.47 USD
-2.03 (-6.66%)
28.55 USD
+0.08 (+0.28%)
We assign a fundamental rating of 5 out of 10 to TGTX. TGTX was compared to 530 industry peers in the Biotechnology industry. TGTX has an average financial health and profitability rating. TGTX is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year TGTX was profitable.
TGTX had a negative operating cash flow in the past year.
In multiple years TGTX reported negative net income over the last 5 years.
TGTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TGTX has a better Return On Assets (43.65%) than 99.25% of its industry peers.
TGTX's Return On Equity of 73.71% is amongst the best of the industry. TGTX outperforms 99.25% of its industry peers.
The Return On Invested Capital of TGTX (9.34%) is better than 94.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 43.65% | ||
| ROE | 73.71% | ||
| ROIC | 9.34% |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TGTX's Profit Margin of 84.11% is amongst the best of the industry. TGTX outperforms 98.49% of its industry peers.
Looking at the Operating Margin, with a value of 19.28%, TGTX belongs to the top of the industry, outperforming 94.34% of the companies in the same industry.
The Gross Margin of TGTX (85.34%) is better than 87.74% of its industry peers.
In the last couple of years the Gross Margin of TGTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.28% | ||
| PM (TTM) | 84.11% | ||
| GM | 85.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TGTX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
Compared to 5 years ago, TGTX has more shares outstanding
TGTX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.81 indicates that TGTX is not in any danger for bankruptcy at the moment.
TGTX has a Altman-Z score of 6.81. This is in the better half of the industry: TGTX outperforms 76.04% of its industry peers.
TGTX has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.40, TGTX is not doing good in the industry: 69.25% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.81 |
ROIC/WACC1.06
WACC8.81%
2.3 Liquidity
A Current Ratio of 3.82 indicates that TGTX has no problem at all paying its short term obligations.
TGTX's Current ratio of 3.82 is in line compared to the rest of the industry. TGTX outperforms 45.85% of its industry peers.
TGTX has a Quick Ratio of 2.89. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.89, TGTX is doing worse than 63.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.82 | ||
| Quick Ratio | 2.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 563.64% over the past year.
TGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 100.88%.
TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 364.59% yearly.
EPS 1Y (TTM)563.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
Revenue 1Y (TTM)100.88%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.79%
3.2 Future
The Earnings Per Share is expected to grow by 92.99% on average over the next years. This is a very strong growth
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.43% yearly.
EPS Next Y1977.65%
EPS Next 2Y265.02%
EPS Next 3Y157.07%
EPS Next 5Y92.99%
Revenue Next Year89.24%
Revenue Next 2Y67.78%
Revenue Next 3Y52.7%
Revenue Next 5Y40.43%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 55.82, the valuation of TGTX can be described as expensive.
TGTX's Price/Earnings ratio is rather cheap when compared to the industry. TGTX is cheaper than 90.57% of the companies in the same industry.
When comparing the Price/Earnings ratio of TGTX to the average of the S&P500 Index (27.19), we can say TGTX is valued expensively.
With a Price/Forward Earnings ratio of 15.26, TGTX is valued correctly.
Based on the Price/Forward Earnings ratio, TGTX is valued cheaper than 95.47% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.88, TGTX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.82 | ||
| Fwd PE | 15.26 |
4.2 Price Multiples
91.13% of the companies in the same industry are more expensive than TGTX, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 47.73 |
4.3 Compensation for Growth
TGTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of TGTX may justify a higher PE ratio.
A more expensive valuation may be justified as TGTX's earnings are expected to grow with 157.07% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y265.02%
EPS Next 3Y157.07%
5. Dividend
5.1 Amount
TGTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
28.47
-2.03 (-6.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners63.66%
Inst Owner Change0%
Ins Owners6.78%
Ins Owner Change-24.82%
Market Cap4.52B
Revenue(TTM)531.90M
Net Income(TTM)447.39M
Analysts78.67
Price Target45.17 (58.66%)
Short Float %16.97%
Short Ratio14.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.98%
Min EPS beat(2)-28.7%
Max EPS beat(2)-23.26%
EPS beat(4)1
Avg EPS beat(4)-14.65%
Min EPS beat(4)-83.83%
Max EPS beat(4)77.18%
EPS beat(8)3
Avg EPS beat(8)0.93%
EPS beat(12)5
Avg EPS beat(12)39.18%
EPS beat(16)8
Avg EPS beat(16)34.08%
Revenue beat(2)1
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-6.11%
Max Revenue beat(2)4.19%
Revenue beat(4)3
Avg Revenue beat(4)1.06%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)6.12%
Revenue beat(8)7
Avg Revenue beat(8)4.47%
Revenue beat(12)9
Avg Revenue beat(12)25.49%
Revenue beat(16)11
Avg Revenue beat(16)25.09%
PT rev (1m)0%
PT rev (3m)4.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.67%
EPS NY rev (1m)0%
EPS NY rev (3m)267.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.82 | ||
| Fwd PE | 15.26 | ||
| P/S | 8.5 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.45 | ||
| P/tB | 7.45 | ||
| EV/EBITDA | 47.73 |
EPS(TTM)0.51
EY1.79%
EPS(NY)1.87
Fwd EY6.55%
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS3.35
BVpS3.82
TBVpS3.82
PEG (NY)0.03
PEG (5Y)N/A
Graham Number6.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 43.65% | ||
| ROE | 73.71% | ||
| ROCE | 11.82% | ||
| ROIC | 9.34% | ||
| ROICexc | 11% | ||
| ROICexgc | 11% | ||
| OM | 19.28% | ||
| PM (TTM) | 84.11% | ||
| GM | 85.34% | ||
| FCFM | N/A |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score5
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 348.98% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 4.2 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.82 | ||
| Quick Ratio | 2.89 | ||
| Altman-Z | 6.81 |
F-Score5
WACC8.81%
ROIC/WACC1.06
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)563.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
EPS Next Y1977.65%
EPS Next 2Y265.02%
EPS Next 3Y157.07%
EPS Next 5Y92.99%
Revenue 1Y (TTM)100.88%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.79%
Revenue Next Year89.24%
Revenue Next 2Y67.78%
Revenue Next 3Y52.7%
Revenue Next 5Y40.43%
EBIT growth 1Y20410.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year378.75%
EBIT Next 3Y148.94%
EBIT Next 5YN/A
FCF growth 1Y-65.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.52%
OCF growth 3YN/A
OCF growth 5YN/A
TG THERAPEUTICS INC / TGTX FAQ
What is the fundamental rating for TGTX stock?
ChartMill assigns a fundamental rating of 5 / 10 to TGTX.
What is the valuation status for TGTX stock?
ChartMill assigns a valuation rating of 6 / 10 to TG THERAPEUTICS INC (TGTX). This can be considered as Fairly Valued.
Can you provide the profitability details for TG THERAPEUTICS INC?
TG THERAPEUTICS INC (TGTX) has a profitability rating of 6 / 10.
Can you provide the financial health for TGTX stock?
The financial health rating of TG THERAPEUTICS INC (TGTX) is 4 / 10.
What is the earnings growth outlook for TG THERAPEUTICS INC?
The Earnings per Share (EPS) of TG THERAPEUTICS INC (TGTX) is expected to grow by 1977.65% in the next year.